Inspirna, Inc.(formerly Rgenix, Inc.)

Inspirna, previously known as Rgenix, is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs that target key pathways in cancers of high unmet need. Inspirna is poised to become a global company with ongoing Phase 3 preparation activities. David Darst co-leads Inspirna’s financing, business and corporate development, and drug development efforts. Thomas manages Inspirna’s corporate records, 401K, HIPAA compliance, human resources, and payroll. Bechar is Inspirna’s Senior Vice President of Clinical Development.​. Corey Sohmer brings to Inspirna more than 25 years of progressive leadership experience in finance and accounting, including approximately 15 years in small to medium size publicly traded biotechnology companies. Inspirna’s mission is to target previously untreatable common cancers with small molecules and biologics by exposing newly discovered drivers of metastasis. Inspirna is developing medicines with oral dosing and safety profiles that we believe will become seamless and simple additions to the existing standard-of-care.